Telik announces patents on TELINTRA compounds

Download PDF Copy

Reviewed

Jun 11 2008

Telik, Inc. announced today that the European Patent Office has issued notices of allowance for two applications covering new compounds related to one of Telik's lead clinical candidates, TELINTRA.

Corresponding applications have already issued as patents in the United States; and other applications are pending in major countries worldwide.

TELINTRA is currently in Phase 2 clinical trials for the treatment of Myelodysplastic Syndrome, a form of pre-leukemia, and for Chemotherapy Induced Neutropenia, a common side effect of chemotherapy. Telik expects these applications and patents to provide broad intellectual property protection to compounds related to TELINTRA, according to Derek Freyberg, Ph.D., Telik's VP, Intellectual Property. The patents will help to broaden and strengthen Telik's intellectual property estate and may support additional clinical development candidates.

Source:

http://www.telik.com/

Posted in: Medical Patent News

Comments (0)

Download PDF Copy

Suggested Reading

Ivonescimab plus chemotherapy provides survival benefit for difficult-to-treat NSCLC patients

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Uncovering a molecular weakness in Ewing sarcoma for targeted therapy

Genetic variant linked to liver injury after chemotherapy in colorectal cancer patients

Innovative topical cream relieves chemotherapy-induced peripheral neuropathy

A new way to monitor chemotherapy drug behavior inside cells

Cervical cancer patients treated with radiation and chemotherapy report greater short-term decline in quality of life

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.